TNFSF11 and cancer: Clinical trials evaluating denosumab for cancer treatment are emerging, and the negative results from trials of treating early‐stage breast cancer and advanced non‐small cell lung carcinoma illustrated the fact that seeking the outlets of anti‐RANKL therapy in cancer immunotherapies was still crucial.81